Remove Blood Pressure Remove Clinical Trials Remove Conditions Remove Document
article thumbnail

CBD Science Update

Project CBD

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Related story Can CBD Help Your Condition? The results were mixed. Preclinical promise.

CBD 218
article thumbnail

CBD Science Update

Project CBD

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Related story Can CBD Help Your Condition? The results were mixed. Preclinical promise.

CBD 177
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. Now, psychedelic research is booming.

History 119
article thumbnail

Curaleaf shares down 8% after FDA sends warning letter over CBD health claims

Cannabis Law Report

Curaleaf CURLF, -7.27% is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” the FDA wrote. Mental conditions like anxiety, depression, and PTSD.”.

CBD 51
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.